Tikvah Therapeutics Enters an Exclusive Licensing Agreement With Apkarian Technologies Related to Agents for Treatment of Pain and Pain-Related Indications

Published: Jul 16, 2007

ATLANTA, July 16, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah) and Chicago-based Apkarian Technologies, LLC (Apkarian) announced today that Tikvah has entered into an exclusive licensing agreement with Apkarian for patents and patent applications involving certain agonists of specific sites of the NMDA receptor.

Back to news